| dc.contributor.author | Dahal, Lekh N. | |
| dc.contributor.author | Basu, Neil | |
| dc.contributor.author | Youssef, Hazem | |
| dc.contributor.author | Khanolkar, Rahul C. | |
| dc.contributor.author | Barker, Robert N. | |
| dc.contributor.author | Erwig, Lars P. | |
| dc.contributor.author | Ward, Frank J. | |
| dc.date.accessioned | 2016-09-09T12:00:07Z | |
| dc.date.available | 2016-09-09T12:00:07Z | |
| dc.date.issued | 2016-08-04 | |
| dc.identifier.citation | Dahal , L N , Basu , N , Youssef , H , Khanolkar , R C , Barker , R N , Erwig , L P & Ward , F J 2016 , ' Immunoregulatory soluble CTLA-4 modifies effector T cell responses in systemic lupus erythematosus ' , Arthritis Research & Therapy , vol. 18 , 180 , pp. 1-11 . https://doi.org/10.1186/s13075-016-1075-1 | en |
| dc.identifier.issn | 1478-6354 | |
| dc.identifier.other | PURE: 69169173 | |
| dc.identifier.other | PURE UUID: 2a90d3a0-e1a7-4236-aad1-38aaca81097e | |
| dc.identifier.other | Scopus: 84984788333 | |
| dc.identifier.uri | http://hdl.handle.net/2164/7465 | |
| dc.description | Acknowledgments This work was supported by Arthritis Research UK (Grant no. 19282). We are grateful to Dr. Nick Fluck for his invaluable support in recruiting patients for the study, and Mrs. Vivien Vaughan for her invaluable expertise in recruiting study participants and maintaining ethical documentation. | en |
| dc.format.extent | 11 | |
| dc.language.iso | eng | |
| dc.relation.ispartof | Arthritis Research & Therapy | en |
| dc.rights | This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. | en |
| dc.subject | SDG 3 - Good Health and Well-being | en |
| dc.subject | Soluble CTLA-4 | en |
| dc.subject | Systemic lupus erythematosus | en |
| dc.subject | Immune regulation | en |
| dc.subject | R Medicine | en |
| dc.subject | Arthritis Research UK (ARUK) | en |
| dc.subject | 19282 | en |
| dc.subject.lcc | R | en |
| dc.title | Immunoregulatory soluble CTLA-4 modifies effector T cell responses in systemic lupus erythematosus | en |
| dc.type | Journal article | en |
| dc.contributor.institution | University of Aberdeen.Applied Medicine | en |
| dc.contributor.institution | University of Aberdeen.Other Applied Health Sciences | en |
| dc.contributor.institution | University of Aberdeen.Epidemiology Group | en |
| dc.contributor.institution | University of Aberdeen.Institute of Medical Sciences | en |
| dc.contributor.institution | University of Aberdeen.Institute of Applied Health Sciences | en |
| dc.description.status | Peer reviewed | en |
| dc.description.version | Publisher PDF | en |
| dc.identifier.doi | https://doi.org/10.1186/s13075-016-1075-1 | |
